Edition:
United States

Gemphire Therapeutics Inc (GEMP.OQ)

GEMP.OQ on NASDAQ Stock Exchange Global Market

1.43USD
4:00pm EDT
Change (% chg)

$-0.11 (-7.14%)
Prev Close
$1.54
Open
$1.53
Day's High
$1.58
Day's Low
$1.42
Volume
57,129
Avg. Vol
148,720
52-wk High
$11.41
52-wk Low
$0.83

Chart for

About

Gemphire Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the development and commercialization of therapeutics to treat cardiovascular and metabolic diseases. It is developing its product candidate, gemcabene (CI-1027), which is a once-daily, oral therapy for patients who are unable to... (more)

Overall

Beta: --
Market Cap(Mil.): $110.31
Shares Outstanding(Mil.): 10.63
Dividend: --
Yield (%): --

Financials

  GEMP.OQ Industry Sector
P/E (TTM): -- 85.68 33.65
EPS (TTM): -2.65 -- --
ROI: -580.12 0.45 14.28
ROE: -3,285.30 1.37 16.00

BRIEF-Gemphire Therapeutics Reports Q1 Loss Per Share Of $0.58

* GEMPHIRE THERAPEUTICS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

May 08 2018

BRIEF-Gemphire Therapeutics Names Steven Gullans CEO

* GEMPHIRE THERAPEUTICS ANNOUNCES THE APPOINTMENT OF STEVEN GULLANS, PH.D., AS PRESIDENT AND CHIEF EXECUTIVE OFFICER

May 03 2018

Earnings vs. Estimates